

Table 23: Clinical evidence profile: Comparison 1.2.2. Mannitol + Dornase alfa versus Dornase alfa alone

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Mannitol + dornase alfa <i>versus</i>	Dornase alfa alone	Relative (95% CI)	Absolute		
FEV₁ (% change from baseline) (follow-up 3 months; range of scores: 0-100; Better indicated by higher values)												
1 (Minaian 2010)	randomised trials ¹	serious ²	no serious inconsistency	serious ³	very serious ⁴	none	20		-	MD 4.3 lower (14.1 lower to 5.5 higher)	VERY LOW	CRITICAL

Abbreviations: CI: confidence interval; FEV₁: forced expiratory volume in 1 second; MD: mean difference
¹ Cross-over design

2 The quality of the evidence was downgraded by 1 because this is an open trial, and there is high risk of incomplete reporting

3 The quality of the evidence was downgraded by 1 as the participants in the trial underwent a tolerance test at screening. Those who fail were not entered in the study, and this limits the generalisability of the results to the general CF population

4 The quality of the evidence was downgraded by 2 as the CI crossed 2 clinical MIDs